Scinai Immunotherapeutics Ltd. (SCNI) News
Follow Scinai Immunotherapeutics Ltd. (SCNI) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 14 public stories across 11 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Scinai Reports Revenue Growth as CDMO Business Expands
An October agreement advances a U.S. customer program to approximately $5.1 million in committed base.
EARNINGS | Nov 05, 2026, 01:02 PM UTC
M
Scinai Immunotherapeutics Secures $5.1M in CDMO Work, Extends Runway to Late 2027
Scinai announced about $5.1 million in committed CDMO services and about $5.3 million in net financing proceeds. It estimates its operating runway will extend to late 2027, with potential extension into Q3 2028 if later
EQUITY | Oct 20, 2026, 12:50 PM UTC
M
Scinai Immunotherapeutics Closes $4.0 Million Private Placement and Warrant Inducement
Scinai Immunotherapeutics said it closed a $4.0 million financing through a private placement and warrant inducement.
EQUITY | Oct 16, 2026, 12:00 PM UTC
L
Scinai Immunotherapeutics announces $4.0 million financing
The financing is through a private placement and warrant inducement.
EQUITY | Oct 14, 2026, 12:01 PM UTC
M
Scinai Signs $5.1M Clinical Manufacturing Deal
Scinai secured a $5.1 million development and clinical manufacturing agreement, expanding its CDMO business.
EQUITY | Oct 13, 2026, 11:01 AM UTC
L
Scinai signs $5.1 million development and clinical manufacturing agreement
Scinai expanded its contract development and manufacturing business through a $5.1 million agreement for development and clinical manufacturing.
EQUITY | Oct 13, 2026, 11:01 AM UTC
L
SCNI - Scinai Regains Compliance with Nasdaq Minimum Bid Price Requirement
SCNI - Scinai Regains Compliance with Nasdaq Minimum Bid Price Requirement
NEWS | Sep 21, 2026, 11:00 AM UTC
L
SCNI - Scinai Concludes PC111 Arrangements and Refocuses Capital on NanoAb Platform and Growing CDMO Business
SCNI - Scinai Concludes PC111 Arrangements and Refocuses Capital on NanoAb Platform and Growing CDMO Business
EQUITY | Sep 08, 2026, 01:19 PM UTC
L
Scinai ends PC111 arrangements, refocuses capital on NanoAb and CDMO
Scinai Immunotherapeutics said it has concluded its PinCell option and license arrangements, concentrating resources on its NanoAb platform and CDMO commercial execution without taking on additional PC111 funding commitm
EQUITY | Sep 08, 2026, 01:19 PM UTC
M
Scinai reports first-half 2026 corporate highlights and results
Scinai reports first-half 2026 corporate highlights and results, with the company highlighting growing CDMO momentum; no numerical results or catalyst were supplied in the wire.
EQUITY | Aug 24, 2026, 11:01 AM UTC
L
Multiple stocks execute reverse splits on Friday Aug 21
BTOG, ELAB, SMTK, SCNI, LIMN and XCH are listed for reverse stock splits ranging from 1-for-5 to 1-for-50 on Friday Aug. 21.
EQUITY | Aug 21, 2026, 09:03 AM UTC
M
Multiple stocks schedule reverse splits for Friday Aug. 21
TradeXchange Newsdesk lists reverse stock splits for BTOG 1-for-5, ELAB 1-for-10, SMTK 1-for-50, SCNI 1-for-10, LIMN 1-for-50, XCH 1-for-20 and MGN 1-for-40 on Friday Aug. 21.
EQUITY | Aug 20, 2026, 08:41 PM UTC
M
Multiple companies announce reverse stock splits for Friday Aug. 21
BTOG, ELAB, SMTK, SCNI, LIMN and XCH are listed for reverse stock splits on Friday Aug. 21, with ratios ranging from 1-for-5 to 1-for-50.
EQUITY | Aug 20, 2026, 07:46 PM UTC
M
Healthcare Stocks Move
Gainers Catheter Precision (AMEX: VTAK ) shares rose 78.2% to $1.55 during Monday's after-market session. The company's market cap stands at $2.2 million. Allarity Therapeutics (NASDAQ: ALLR ) stock increased by 8.08% to
EQUITY | Jun 22, 2026, 09:10 PM UTC